Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmakerâs second drug development setback since November.
The Food and Drug Administration said in a letter to the company that it needed more information about the drugâs safety and the best doses, Lilly said Friday in a statement.
Lilly said it disagrees with FDAâs conclusions but will work with the agency on a plan to eventually get the drug, baracitinib, approved for U.S...
Share this post
← Back to Utah